Michael Davidson Acquires 10,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CEO Michael Davidson bought 10,000 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were purchased at an average price of $22.65 per share, with a total value of $226,500.00. Following the completion of the acquisition, the chief executive officer owned 792,923 shares of the company’s stock, valued at $17,959,705.95. This trade represents a 1.28% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS opened at $21.18 on Thursday. The stock’s 50-day moving average is $27.74 and its 200 day moving average is $30.89. The company has a market cap of $2.53 billion, a PE ratio of -9.81 and a beta of 0.09. NewAmsterdam Pharma Company N.V. has a 1 year low of $21.02 and a 1 year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. The company had revenue of $3.70 million during the quarter, compared to the consensus estimate of $2.83 million. Analysts expect that NewAmsterdam Pharma Company N.V. will post -1.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NAMS. Royal Bank Of Canada decreased their price target on shares of NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Jefferies Financial Group reaffirmed a “buy” rating and set a $45.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. BMO Capital Markets assumed coverage on NewAmsterdam Pharma in a research report on Monday, July 20th. They issued an “outperform” rating and a $58.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and issued a $52.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, September 8th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.73.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Engineers Gate Manager LP bought a new stake in NewAmsterdam Pharma in the second quarter worth $662,000. Squarepoint Ops LLC boosted its stake in NewAmsterdam Pharma by 113.9% in the 2nd quarter. Squarepoint Ops LLC now owns 92,026 shares of the company’s stock worth $3,119,000 after purchasing an additional 49,005 shares in the last quarter. Arizona State Retirement System boosted its stake in NewAmsterdam Pharma by 34.6% in the 2nd quarter. Arizona State Retirement System now owns 16,656 shares of the company’s stock worth $564,000 after purchasing an additional 4,281 shares in the last quarter. Frazier Life Sciences Management L.P. grew its position in NewAmsterdam Pharma by 6.8% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company’s stock valued at $613,033,000 after purchasing an additional 1,145,128 shares during the last quarter. Finally, Bank of America Corp DE grew its position in NewAmsterdam Pharma by 84.4% during the 1st quarter. Bank of America Corp DE now owns 847,089 shares of the company’s stock valued at $27,115,000 after purchasing an additional 387,698 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, particularly conditions involving elevated cholesterol and residual cardiovascular risk. The company’s lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and improve other lipid parameters.

Obicetrapib has been evaluated in several clinical studies, including the Phase 3 BROADWAY trial, for patients whose cholesterol levels remain inadequately controlled despite the use of existing lipid-lowering treatments.